array(40) {
  [0]=>
  string(4) "1806"
  ["article_id"]=>
  string(4) "1806"
  [1]=>
  string(53) "Japanese approval for Lupin’s etanercept biosimilar"
  ["article_title"]=>
  string(53) "Japanese approval for Lupin’s etanercept biosimilar"
  [2]=>
  string(150) "Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 26 March 2019 that its joint venture YL Biologics and Lupin (through its Japan"
  ["short_description"]=>
  string(150) "Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 26 March 2019 that its joint venture YL Biologics and Lupin (through its Japan"
  [3]=>
  string(376) "
Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 26 March 2019 that its joint venture YL Biologics and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry) had received approval from Japan’s medicines regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA), for its etanercept biosimilar YLB113 in Japan.
"
  ["description"]=>
  string(376) "
Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 26 March 2019 that its joint venture YL Biologics and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry) had received approval from Japan’s medicines regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA), for its etanercept biosimilar YLB113 in Japan.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(95) "http://www.gabionline.net//Biosimilars/News/Japanese-approval-for-Lupin-s-etanercept-biosimilar"
  ["blog_url"]=>
  string(95) "http://www.gabionline.net//Biosimilars/News/Japanese-approval-for-Lupin-s-etanercept-biosimilar"
  [15]=>
  string(19) "2019-04-01 17:41:29"
  ["add_date"]=>
  string(19) "2019-04-01 17:41:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-01 21:02:39"
  ["create_at"]=>
  string(19) "2019-04-01 21:02:39"
  [19]=>
  string(53) "Japanese_approval_for_Lupin___s_etanercept_biosimilar"
  ["slug"]=>
  string(53) "Japanese_approval_for_Lupin___s_etanercept_biosimilar"
}
                    

array(40) {
  [0]=>
  string(4) "1807"
  ["article_id"]=>
  string(4) "1807"
  [1]=>
  string(40) "Use of biosimilars in oncology in Europe"
  ["article_title"]=>
  string(40) "Use of biosimilars in oncology in Europe"
  [2]=>
  string(155) "Dr Elena Wolff-Holz gave a presentation at the European Commission’s Multi-Stakeholder Conference, which was held in Brussels, Belgium on 14 Septemb"
  ["short_description"]=>
  string(155) "Dr Elena Wolff-Holz gave a presentation at the European Commission’s Multi-Stakeholder Conference, which was held in Brussels, Belgium on 14 Septemb"
  [3]=>
  string(235) "
Dr Elena Wolff-Holz gave a presentation at the European Commission’s Multi-Stakeholder Conference, which was held in Brussels, Belgium on 14 September 2018 giving an overview of biosimilars approved in Europe to date [1].
"
  ["description"]=>
  string(235) "
Dr Elena Wolff-Holz gave a presentation at the European Commission’s Multi-Stakeholder Conference, which was held in Brussels, Belgium on 14 September 2018 giving an overview of biosimilars approved in Europe to date [1].
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(75) "http://www.gabionline.net//Reports/Use-of-biosimilars-in-oncology-in-Europe"
  ["blog_url"]=>
  string(75) "http://www.gabionline.net//Reports/Use-of-biosimilars-in-oncology-in-Europe"
  [15]=>
  string(19) "2019-04-01 17:27:37"
  ["add_date"]=>
  string(19) "2019-04-01 17:27:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-01 21:02:39"
  ["create_at"]=>
  string(19) "2019-04-01 21:02:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1808"
  ["article_id"]=>
  string(4) "1808"
  [1]=>
  string(90) "Anti-price gouging: legislation introduced in Senate while Maryland’s appeal is rejected"
  ["article_title"]=>
  string(90) "Anti-price gouging: legislation introduced in Senate while Maryland’s appeal is rejected"
  [2]=>
  string(150) "Under current law in the US, pharmaceutical companies can raise prices of their products without justification. A 2017 Public Citizen survey revealed "
  ["short_description"]=>
  string(150) "Under current law in the US, pharmaceutical companies can raise prices of their products without justification. A 2017 Public Citizen survey revealed "
  [3]=>
  string(489) "
Under current law in the US, pharmaceutical companies can raise prices of their products without justification. A 2017 Public Citizen survey revealed that only 14% of the world’s top 29 pharmaceutical companies were willing to limit annual price increases to less than 10%. In February 2019, US senators proposed legislation to reduce prescription drug price gouging, while Maryland’s appeal of a ruling that struck down its anti-price gouging regulation was rejected.
"
  ["description"]=>
  string(489) "
Under current law in the US, pharmaceutical companies can raise prices of their products without justification. A 2017 Public Citizen survey revealed that only 14% of the world’s top 29 pharmaceutical companies were willing to limit annual price increases to less than 10%. In February 2019, US senators proposed legislation to reduce prescription drug price gouging, while Maryland’s appeal of a ruling that struck down its anti-price gouging regulation was rejected.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(135) "http://www.gabionline.net//Policies-Legislation/Anti-price-gouging-legislation-introduced-in-Senate-while-Maryland-s-appeal-is-rejected"
  ["blog_url"]=>
  string(135) "http://www.gabionline.net//Policies-Legislation/Anti-price-gouging-legislation-introduced-in-Senate-while-Maryland-s-appeal-is-rejected"
  [15]=>
  string(19) "2019-04-01 15:51:36"
  ["add_date"]=>
  string(19) "2019-04-01 15:51:36"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-01 21:02:39"
  ["create_at"]=>
  string(19) "2019-04-01 21:02:39"
  [19]=>
  string(90) "Anti-price_gouging__legislation_introduced_in_Senate_while_Maryland___s_appeal_is_rejected"
  ["slug"]=>
  string(90) "Anti-price_gouging__legislation_introduced_in_Senate_while_Maryland___s_appeal_is_rejected"
}
                    

array(40) {
  [0]=>
  string(4) "1933"
  ["article_id"]=>
  string(4) "1933"
  [1]=>
  string(127) "FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65"
  ["article_title"]=>
  string(127) "FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65"
  [2]=>
  string(150) "LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, ha"
  ["short_description"]=>
  string(150) "LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, ha"
  [3]=>
  string(247) "LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, has received approval from the U.S. Food and Drug Administration (FDA) for the reintroduction of..."
  ["description"]=>
  string(247) "LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, has received approval from the U.S. Food and Drug Administration (FDA) for the reintroduction of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-reintroduction-zelnorm-tegaserod-irritable-bowel-syndrome-constipation-ibs-c-women-4941.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+the+Reintroduction+of+Zelnorm+%28tegaserod%29+for+Irritable+Bowel+Syndrome+with+Constipation+%28IBS-C%29+in"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-reintroduction-zelnorm-tegaserod-irritable-bowel-syndrome-constipation-ibs-c-women-4941.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+the+Reintroduction+of+Zelnorm+%28tegaserod%29+for+Irritable+Bowel+Syndrome+with+Constipation+%28IBS-C%29+in"
  [15]=>
  string(19) "2019-04-01 14:04:05"
  ["add_date"]=>
  string(19) "2019-04-01 14:04:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2000"
  ["article_id"]=>
  string(4) "2000"
  [1]=>
  string(85) "Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1"
  ["article_title"]=>
  string(85) "Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1"
  [2]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) April 1, 2019 --AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announce"
  ["short_description"]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) April 1, 2019 --AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announce"
  [3]=>
  string(248) "KENILWORTH, N.J.--(BUSINESS WIRE) April 1, 2019 --AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation..."
  ["description"]=>
  string(248) "KENILWORTH, N.J.--(BUSINESS WIRE) April 1, 2019 --AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(259) "https://www.drugs.com/clinical_trials/selumetinib-granted-u-s-breakthrough-therapy-designation-neurofibromatosis-type-1-18123.html?utm_source=ddc&utm_medium=rss&utm_campaign=Selumetinib+Granted+U.S.+Breakthrough+Therapy+Designation+in+Neurofibromatosis+Type+1"
  ["blog_url"]=>
  string(259) "https://www.drugs.com/clinical_trials/selumetinib-granted-u-s-breakthrough-therapy-designation-neurofibromatosis-type-1-18123.html?utm_source=ddc&utm_medium=rss&utm_campaign=Selumetinib+Granted+U.S.+Breakthrough+Therapy+Designation+in+Neurofibromatosis+Type+1"
  [15]=>
  string(19) "2019-04-01 13:04:48"
  ["add_date"]=>
  string(19) "2019-04-01 13:04:48"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2001"
  ["article_id"]=>
  string(4) "2001"
  [1]=>
  string(83) "Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1"
  ["article_title"]=>
  string(83) "Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1"
  [2]=>
  string(150) "1 April 2019 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and D"
  ["short_description"]=>
  string(150) "1 April 2019 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and D"
  [3]=>
  string(252) "1 April 2019 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational..."
  ["description"]=>
  string(252) "1 April 2019 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(256) "https://www.drugs.com/clinical_trials/selumetinib-granted-us-breakthrough-therapy-designation-neurofibromatosis-type-1-18108.html?utm_source=ddc&utm_medium=rss&utm_campaign=Selumetinib+Granted+US+Breakthrough+Therapy+Designation+in+Neurofibromatosis+Type+1"
  ["blog_url"]=>
  string(256) "https://www.drugs.com/clinical_trials/selumetinib-granted-us-breakthrough-therapy-designation-neurofibromatosis-type-1-18108.html?utm_source=ddc&utm_medium=rss&utm_campaign=Selumetinib+Granted+US+Breakthrough+Therapy+Designation+in+Neurofibromatosis+Type+1"
  [15]=>
  string(19) "2019-04-01 08:04:12"
  ["add_date"]=>
  string(19) "2019-04-01 08:04:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4880"
  ["article_id"]=>
  string(4) "4880"
  [1]=>
  string(48) "5th World Congress on Spine and Spinal Disorders"
  ["article_title"]=>
  string(48) "5th World Congress on Spine and Spinal Disorders"
  [2]=>
  string(150) "Spine 2019 welcomes attendees, presenters, and exhibitors from all over the world to Rome. We are delighted to invite you all to attend and register f"
  ["short_description"]=>
  string(150) "Spine 2019 welcomes attendees, presenters, and exhibitors from all over the world to Rome. We are delighted to invite you all to attend and register f"
  [3]=>
  string(502) "Spine 2019 welcomes attendees, presenters, and exhibitors from all over the world to Rome. We are delighted to invite you all to attend and register for the 5th World Congress on Spine and Spinal Disorders which is organized by PULSUS GROUP during October 16-17, 2019 in Rome, Italy.&#nlSpine 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia..."
  ["description"]=>
  string(502) "Spine 2019 welcomes attendees, presenters, and exhibitors from all over the world to Rome. We are delighted to invite you all to attend and register for the 5th World Congress on Spine and Spinal Disorders which is organized by PULSUS GROUP during October 16-17, 2019 in Rome, Italy.&#nlSpine 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(80) "https://www.pharmiweb.com/event/5th-world-congress-on-spine-and-spinal-disorders"
  ["blog_url"]=>
  string(80) "https://www.pharmiweb.com/event/5th-world-congress-on-spine-and-spinal-disorders"
  [15]=>
  string(19) "2019-03-29 20:56:42"
  ["add_date"]=>
  string(19) "2019-03-29 20:56:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6580"
  ["article_id"]=>
  string(4) "6580"
  [1]=>
  string(58) "Impact of Brexit on the Pharma & Medical Device Industries"
  ["article_title"]=>
  string(58) "Impact of Brexit on the Pharma & Medical Device Industries"
  [2]=>
  string(150) "Hear the latest information from our expert speaker panel to help you understand the changes that are required and ensure you are up to date with Brex"
  ["short_description"]=>
  string(150) "Hear the latest information from our expert speaker panel to help you understand the changes that are required and ensure you are up to date with Brex"
  [3]=>
  string(153) "Hear the latest information from our expert speaker panel to help you understand the changes that are required and ensure you are up to date with Brexit!"
  ["description"]=>
  string(153) "Hear the latest information from our expert speaker panel to help you understand the changes that are required and ensure you are up to date with Brexit!"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(90) "https://www.pharmiweb.com/event/impact-of-brexit-on-the-pharma-medical-device-industries-1"
  ["blog_url"]=>
  string(90) "https://www.pharmiweb.com/event/impact-of-brexit-on-the-pharma-medical-device-industries-1"
  [15]=>
  string(19) "2019-03-29 19:39:09"
  ["add_date"]=>
  string(19) "2019-03-29 19:39:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:22:05"
  ["create_at"]=>
  string(19) "2019-11-26 10:22:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4860"
  ["article_id"]=>
  string(4) "4860"
  [1]=>
  string(59) "Pharmaceutical Packaging, Labelling and Artwork Origination"
  ["article_title"]=>
  string(59) "Pharmaceutical Packaging, Labelling and Artwork Origination"
  [2]=>
  string(150) "This course has been designed to present a number of important developments in pharmaceutical packaging and labelling from regulations, standardisatio"
  ["short_description"]=>
  string(150) "This course has been designed to present a number of important developments in pharmaceutical packaging and labelling from regulations, standardisatio"
  [3]=>
  string(200) "This course has been designed to present a number of important developments in pharmaceutical packaging and labelling from regulations, standardisation, technology, innovation and artwork origination."
  ["description"]=>
  string(200) "This course has been designed to present a number of important developments in pharmaceutical packaging and labelling from regulations, standardisation, technology, innovation and artwork origination."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(90) "https://www.pharmiweb.com/event/pharmaceutical-packaging-labelling-and-artwork-origination"
  ["blog_url"]=>
  string(90) "https://www.pharmiweb.com/event/pharmaceutical-packaging-labelling-and-artwork-origination"
  [15]=>
  string(19) "2019-03-29 19:11:28"
  ["add_date"]=>
  string(19) "2019-03-29 19:11:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2002"
  ["article_id"]=>
  string(4) "2002"
  [1]=>
  string(147) "Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients"
  ["article_title"]=>
  string(147) "Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients"
  [2]=>
  string(150) "FOSTER CITY, Calif. and MECHELEN, Belgium--(BUSINESS WIRE)--Mar. 28, 2019-- regulated information– Gilead Sciences, Inc. (NASDAQ: GILD) and Gala"
  ["short_description"]=>
  string(150) "FOSTER CITY, Calif. and MECHELEN, Belgium--(BUSINESS WIRE)--Mar. 28, 2019-- regulated information– Gilead Sciences, Inc. (NASDAQ: GILD) and Gala"
  [3]=>
  string(247) "FOSTER CITY, Calif. and MECHELEN, Belgium--(BUSINESS WIRE)--Mar. 28, 2019-- regulated information– Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 3, an ongoing,..."
  ["description"]=>
  string(247) "FOSTER CITY, Calif. and MECHELEN, Belgium--(BUSINESS WIRE)--Mar. 28, 2019-- regulated information– Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 3, an ongoing,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/gilead-galapagos-announce-filgotinib-meets-primary-endpoint-phase-3-finch-3-study-methotrexate-na-18124.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+and+Galapagos+Announce+Filgotinib+Meets+Primary+Endpoint+in+the+Phase+3+FINCH+3+Study+in+Methotrexate-N"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/gilead-galapagos-announce-filgotinib-meets-primary-endpoint-phase-3-finch-3-study-methotrexate-na-18124.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+and+Galapagos+Announce+Filgotinib+Meets+Primary+Endpoint+in+the+Phase+3+FINCH+3+Study+in+Methotrexate-N"
  [15]=>
  string(19) "2019-03-29 06:03:47"
  ["add_date"]=>
  string(19) "2019-03-29 06:03:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2003"
  ["article_id"]=>
  string(4) "2003"
  [1]=>
  string(141) "Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas"
  ["article_title"]=>
  string(141) "Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas"
  [2]=>
  string(150) "WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics "
  ["short_description"]=>
  string(150) "WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics "
  [3]=>
  string(252) "WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced results..."
  ["description"]=>
  string(252) "WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced results..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/proteon-therapeutics-announces-top-line-results-phase-3-patency-2-clinical-trial-vonapanitase-18116.html?utm_source=ddc&utm_medium=rss&utm_campaign=Proteon+Therapeutics+Announces+Top-Line+Results+From+Phase+3+PATENCY-2+Clinical+Trial+of+Vonapanitase+in+Radioceph"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/proteon-therapeutics-announces-top-line-results-phase-3-patency-2-clinical-trial-vonapanitase-18116.html?utm_source=ddc&utm_medium=rss&utm_campaign=Proteon+Therapeutics+Announces+Top-Line+Results+From+Phase+3+PATENCY-2+Clinical+Trial+of+Vonapanitase+in+Radioceph"
  [15]=>
  string(19) "2019-03-28 14:04:46"
  ["add_date"]=>
  string(19) "2019-03-28 14:04:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2004"
  ["article_id"]=>
  string(4) "2004"
  [1]=>
  string(156) "Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer"
  ["article_title"]=>
  string(156) "Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer"
  [2]=>
  string(150) "BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO:"
  ["short_description"]=>
  string(150) "BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO:"
  [3]=>
  string(248) "BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the..."
  ["description"]=>
  string(248) "BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/seattle-genetics-astellas-announce-positive-topline-results-pivotal-trial-enfortumab-vedotin-18114.html?utm_source=ddc&utm_medium=rss&utm_campaign=Seattle+Genetics+and+Astellas+Announce+Positive+Topline+Results+from+Pivotal+Trial+of+Enfortumab+Vedotin+in+Locally"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/seattle-genetics-astellas-announce-positive-topline-results-pivotal-trial-enfortumab-vedotin-18114.html?utm_source=ddc&utm_medium=rss&utm_campaign=Seattle+Genetics+and+Astellas+Announce+Positive+Topline+Results+from+Pivotal+Trial+of+Enfortumab+Vedotin+in+Locally"
  [15]=>
  string(19) "2019-03-28 14:04:40"
  ["add_date"]=>
  string(19) "2019-03-28 14:04:40"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}